LUND, Sweden, Nov. 17, 2020 /PRNewswire/ -- Immunovia AB
(publ) ("Immunovia") announced today that Immunovia's Chief
Executive Officer, Patrik Dahlen,
has acquired Immunovia 15,000 shares for 2.5 MSEK on the open
market and his total holding is now 45,000 shares.
For more information, please contact:
Julie Silber, Director of
Investor Relations, Immunovia
Email: julie.silber@immunovia.com
Tel: +46 7 93 486 277
The information was submitted for publication, through the
agency of the contact person set out above, at 17:30 CET on November 17,
2020.
About Immunovia
Immunovia AB is a diagnostic company that is developing and
commercializing highly accurate blood tests for the early detection
of cancer and autoimmune diseases based on Immunovia's
proprietary test platform called IMMray™. Tests are based on
antibody biomarker microarray analysis using advanced
machine-learning and bioinformatics to single-out a set of relevant
biomarkers that indicate a certain disease. Thus, forming a unique
"disease biomarker signature".
The company was founded in 2007, based on cancer studies and
ground-breaking research in the Department of Immuntechnology at
Lund University and CREATE Health
Cancer Center, Sweden.
The first product, IMMray™ PanCan-d, is undergoing clinical
evaluation in some of the world's largest clinical studies for
pancreatic cancer, PanFAM-1, PanSYM-1 and PanDIA-1 and is
currently in the final validation phase. The company aims for a
sales start at the end of Q1 2021 with subsequent commercial
testing in Q2.
When validated, IMMray™ PanCan-d will be the first blood-based
test for early diagnosis of pancreatic cancer on the market, with a
potential to significantly improve patient survival and
outcome.
Immunovia Dx Laboratories located in Marlborough, Massachusetts, USA and
Lund, Sweden will provide
laboratory testing services in two accredited reference
laboratories.
Immunovia's shares (IMMNOV) are listed on Nasdaq Stockholm. For
more information, please visit www.immunovia.com.
This information was brought to you by Cision
http://news.cision.com
https://news.cision.com/immunovia-ab/r/chief-executive-officer--patrik-dahlen-buys-immunovia-shares,c3238889
The following files are available for download:
https://mb.cision.com/Main/13121/3238889/1336345.pdf
|
Release
|
View original
content:http://www.prnewswire.com/news-releases/chief-executive-officer-patrik-dahlen-buys-immunovia-shares-301175081.html
SOURCE Immunovia AB